Company Name
Grand Shuyang Life Sciences (Chengdu) Co.,Ltd.
Year of Establishment
1985
Enterprise Size
more than 1000
Annual Turnover(USD)
More than 99,999,999
Company Introduction
For half a century, Grand Shuyang has continuously innovated and developed in the field of blood (Plasma Derived) products, becoming one of China’s leading high-tech enterprises in this industry. It focuses on both domestic and global markets and boasts a modern production base that integrates automation and information technology, covering the entire product chain and ranking among the top in China in terms of production capacity. Grand Shuyang continuously expands its Plasma-derived product pipeline, including:
Human Albumin · Human Immunoglobulin (pH4) Intravenous INJ · Hepatitis B Human Immunoglobulin (pH4) Intravenous INJ · Hepatitis B Human Immunoglobulin · Tetanus Human Immunoglobulin · Rabies Human Immunoglobulin · Human Immunoglobulin for Intramuscular INJ · Histamine Human Immunoglobulin · Human Coagulation Factor IX · Human Fibrinogen and recombinant and cell gene therapy products.
Shuyang has been developing its international market for 20 years and was the first Chinese PDMP manufacturer to successfully export blood products overseas. Currently, 7 of its products are registered and exported to 24 countries across Asia, Eastern Europe, and Central and South America, contributing to consistent sales growth in these regions. In recent years, overseas income has ranked among the top in China.
-GMP approved in China, PIC/S, and EAEU.
-ISO 9001/14001/45001 approved.
-50+ patents granted.
-National and provincial honors over the years.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Production Capacity,Buyers' Specifications Accepted,Quality Service,
Patents and Copyright
The ‘preservative-free dual viral inactivation process’ developed and invented independently by the company has obtained a patent certificate issued by the United States Patent and Trademark Office, with Patent No. US006338849B1, a patent certificate issued by IP Australia, with Patent No. 756017, and a patent certificate issued by the State Intellectual Property Office of P. R. China, with Patent No. ZL98112108.X.
Milestone
In 1985, Chengdu Shuyang Pharmaceutical Factory was established and is affiliated to the Chengdu Military Region Enterprise Management Bureau
In 1994, Sichuan Shuyang Enterprise (Group) Co., Ltd. was established
In 1998, it was affiliated to the Chengdu Medical Administration Bureau
In 2001, it was reorganized and renamed Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., which is affiliated to China Grand Group
In 2008, it was restructured into a joint-stock company
In 2024, it was renamed Grand Shuyang Life Sciences (Chengdu) Co., Ltd.